Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

RTW Investments acquired 1,181,990 IRTC shares during Q4 2025, with an estimated position value of $210 million based on the 13F reported at quarter-end. The position represents 2.1% of RTW's 13F reportable AUM.

SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth.

The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.

iRhythm Holdings, Inc. (IRTC) Q4 2025 Earnings Call Transcript

iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago.

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $208.9 million, a 27.1% increase compared to fourth quarter 2024 Gross margin of 70.9%, a 90-basis point increase compared to fourth quarter 2024 Net income of $5.6 million, a $6.9 million improvement compared to fourth quarter 2024 and the first quarter of positive GAAP net income in Company history Adjusted EBITDA and adjusted EBITDA margin of $34.3 million and 16.4%, respectively, a $15.0 million and 470-basis point improvement, respectively, compared to fourth quarter 2024 Unrestricted cash, cash equivalents and marketable securities of $583.8 million at December 31, 2025, a $18.6 million increase from September 30, 2025 Full Year 2025 Financial Highlights Revenue of $747.1 million, a 26.2% increase compared to full year 2024 Gross margin of 70.6%, a 170-basis point increase compared to full year 2024 Net loss of $44.6 million, a $68.7 million improvement compared to full year 2024 Adjusted EBITDA and adjusted EBITDA margin of $68.9 million and 9.2%, respectively, a $76.7 million and 1,050-basis point improvement, respectively compared to full year 2024 Free cash flow of $34.5 million, the first year of positive free cash flow in Company history Recent Operational Highlights Record quarterly revenue and fifth consecutive quarterly revenue above 20% year-over-year growth, driven by volume across our US core business, innovative health channels, and international markets Upcoming data presentations at the American College of Cardiology's Annual Scientific Session & Expo in New Orleans, Louisiana, from March 28 – 30, 2026 “The fourth quarter capped a transformational year for iRhythm,” said Quentin Blackford, President and Chief Executive Officer of iRhythm.

SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.